Tracers / [68Ga]NOTA-ABDC2
[68Ga]NOTA-ABDC2
Also written as [Ga-68]Ga-NOTA-ABDC2
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Nanobody-albumin binding domain fusion protein (NOTA-conjugated CD47-targeting nanobody)
- Target / mechanism
- CD47-targeting agent PMID 36939440
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 12.85% ± 0.45 (n = 2) no | >99% | NOTA-ABDC2 | 36939440 2023 Research (Wash D C) The detailed methods for chelator conjugation, 68Ga/89Zr/177Lu-labeling, and quality control of the tracers are provided in the supplemental file. — The nondecay corrected radiochemical yield of [68Ga]Ga-NOTA-C2, [68Ga]Ga-NOTA-ABDC2, and [89Zr]Zr-DFO-ABDC2 were 25.15% ± 10.21 (n = 4), 12.85% ± 0.45 (n = 2), and 99% (n = 1), respectively. |
Need this precursor?We can point you to suppliers for [68Ga]NOTA-ABDC2, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36939440. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.